Expansion Opportunities Qureight expansion to London and Northern Europe signals a broadened geographic footprint and access to larger talent pools in ML, commercial, and clinical operations. This creates opportunities to offer scaled imaging workflows, regional CRO services, and collaborative trials across Europe.

Series B Momentum With a $20M Series B led by Molten Ventures and new board addition, Qureight is accelerating growth and technology investments. This indicates an openness to strategic partnerships, co-development deals, and expansion of AI-driven imaging capabilities for early-phase and late-stage trials.

AI Model Focus Development of disease-specific deep learning models in a short development cycle suggests potential for bespoke endpoint solutions and accelerated trial readouts. Sales opportunities include offering tailored AI endpoints, rapid model deployment, and subscription access to disease-specific analytics.

Clinical Focus Areas Specialization in IPF, progressive pulmonary fibrosis, bronchiectasis, and pulmonary hypertension aligns with high-need therapeutic areas. This positions Qureight to target sponsors focused on respiratory and cardio-pulmonary trials with end-to-end imaging curation and validation services.

Strategic Partnerships Recent collaboration for inhaled pirfenidone evaluation (AP01) demonstrates readiness for joint development and protocol-driven studies. This creates sales openings for risk-sharing engagements, SCA-enabled studies, and integrated imaging analytics partnerships tied to novel therapies.